PMID-41359966 – GLP-1RA Cancer Risk: Systematic Review of 94,245 Patients
Ko K et al. "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials," Annals of Internal Medicine, 2026. doi:10.7326/ANNALS-25-02237
Quick Reference
| Property | Value |
|---|---|
| PMID | 41359966 |
| DOI | 10.7326/ANNALS-25-02237 |
| Year | 2026 |
| Journal | Annals of Internal Medicine |
| Study Type | Systematic Review / Meta-analysis |
| Evidence Level | I |
| Sample | 94,245 patients across 48 RCTs |
| Peptide(s) Studied | Semaglutide, Tirzepatide |
Key Findings
- Largest meta-analysis to date examining GLP-1RA cancer risk across 48 RCTs with 94,245 patients
- Overall conclusion: "Little or no effect" of GLP-1RAs on cancer risk
- No significant increase in thyroid cancer risk (addressing the long-standing rodent C-cell concern)
- No significant increase in pancreatic cancer risk
- No significant increase in breast cancer risk
- No significant increase in kidney cancer risk
- Results consistent across individual GLP-1RA agents (semaglutide, liraglutide, dulaglutide, tirzepatide)
- Duration of exposure analysis showed no emerging signal with longer use
Study Design
Systematic review and meta-analysis restricted to randomized controlled trials only, providing the highest-quality evidence synthesis. Searched multiple databases for all published RCTs of GLP-1 receptor agonists reporting cancer outcomes. 48 RCTs included with a total of 94,245 participants. Pre-specified subgroup analyses by cancer type, specific GLP-1RA agent, and duration of treatment.
Limitations
- RCT follow-up durations may be insufficient to capture long-latency cancers (most trials 1-3 years)
- Cancer was a secondary or adverse-event endpoint in all included trials, not a primary outcome
- Relatively small number of cancer events limits power for rare cancer types
- Heterogeneous patient populations (T2D, obesity, cardiovascular prevention)
Clinical Relevance
This is the definitive reassurance study for GLP-1RA cancer safety as of 2026. Published in Annals of Internal Medicine with the largest patient sample to date, it should be the primary citation when counseling patients about GLP-1RA cancer risk. Directly relevant for semaglutide and tirzepatide prescribing. Largely resolves the thyroid cancer concern that originated from rodent studies (PMID-20203154), though post-marketing surveillance should continue.
Related
#research #systematic-review #evidence-level-I #cancer